The RevLite O-switched Nd: YAG Laser System is indicated for Incision, Excision, Ablation, Vaporization of Soft Tissue for General Dermatology, Dermatologic and General Surgical Procedures for Coagulation and Hemostasis.

Specific Indications

1064 nm wavelength:

Tattoo Removal: Dark Ink: (Black & Blue)

Nevus of Ota

Removal or lightening of unwanted hair with or without adjuvant preparation.

Skin resurfacing procedures for the treatment of acne scars and wrinkles

532 nm wavelength (nominal delivered energy of 585nm and 650 nm with the Optional Multilite Dye Laser Handpiece):

Tattoo Removal: Light Ink (Red, Sky Blue, Green)

Treatment of Vascular Lesions including, but not limited to:

. Prot wine birthmarks
Telangiectasias .
Spider angioma .
Cherry angioma .
Spider nevi .

Treatment of Pigmented Lesions including, but not limited to:

Café-au-lait bithmarks .
Solar lentiginos .
Senile lentiginos .
Becker's nevi .
Freckles .
Nevus spilus .

Skin resurfacing procedures for the treatment of acne scars and wrinkles.

Device Description

The RevLite System with LCD Panel laser unit and controls are contained in a single console. Electrical power is supplied to the console by the facility's power source. Laser energy produced within the device is delivered to the tissue by means of an articulated arm and a specially designed MultiSpot Handpiece or optional Multilite Dye Laser Handpieces. The user activates laser emission by means of a footswitch. The RevLite System incorporates 2 very narrow laser applications designed to apply more energy over a larger spot size at the same fluence level, enabling the physician to treat a larger area more rapidly.

AI/ML Overview

The provided K063834 RevLite Q-Switched Laser System did not include any clinical performance data or studies. The submission explicitly states "Nonclinical Performance Data: None" and "Clinical Performance Data: none".

Therefore, I cannot provide a table of acceptance criteria and reported device performance, nor can I answer any of the subsequent questions related to a study, as no such study is described in this document.

The FDA's decision was based on a comparison to an equivalent device (RevLite C6 Q-Switched Nd: YAG Laser System - K063112) in terms of indications for use, technical specifications, operating performance features, and general design features, rather than on new performance data for this specific submission.

Summary

{0}------------------------------------------------

K063834

RevLite Q-Switched Laser System 510k Summary

Image /page/0/Picture/3 description: The image shows the logo for HOYA ConBio, along with their address, phone number, website, and fax number. The address is 47733 Fremont Boulevard, Fremont, California 94538. The phone number is 510-445-4500, the website is www.conbio.com, and the fax number is 510-445-4550.

/JAN 2 ວ 2007

Submitter:	Hoya ConBio, Inc.47733 Fremont Blvd.Fremont, California 94538Phone: 510-445-4500Fax: 510-445-4550
Contact:	Donna K. TemplemanRegulatory Consultant
Date Summary Prepared:	December 21, 2006
Device Trade Name:	RevLite™ Q-Switched Nd: YAG Laser System
Common Name:	Dermatology Laser System
Classification Name:	Instrument, surgical, powered, laser79-GEX
Classification Code:	878.4810 Laser surgical instrument for use in general and plasticsurgery and in dermatology (1) A carbon dioxide laser for use ingeneral surgery and in dermatology is a laser device intended tocut, destroy, or remove tissue by light energy emitted by carbondioxide.(2) An argon laser for use in dermatology is a laser deviceintended to destroy or coagulate tissue by light energy emitted byargon.
Equivalent Device:	RevLite C6 Q-Switched Nd: YAG Laser System - K063112
Device Description:	The RevLite System with LCD Panel laser unit and controls arecontained in a single console. Electrical power is supplied to theconsole by the facility's power source. Laser energy producedwithin the device is delivered to the tissue by means of anarticulated arm and a specially designed MultiSpot Handpiece oroptional Multilite Dye Laser Handpieces. The user activates laseremission by means of a footswitch. The RevLite Systemincorporates 2 very narrow laser applications designed to applymore energy over a larger spot size at the same fluence level,enabling the physician to treat a larger area more rapidly.
Intended Use:	For use in dermatology for the following indications: Treatmentof Epidermal Pigmented Lesions, Treatment of DermalPigmented Lesions Nevus of Ota, Incision, Excision, Ablation,Vaporization of Soft Tissue for General Dermatology,Dermatologic and General Surgical Procedures for Coagulationand Hemostasis, Laser skin resurfacing procedures for thetreatment of acne scars and wrinkles, Tattoo Removal: Dark Ink:(Black & Blue) Light Ink: (Red, Sky Blue, Green), Treatment ofVascular Lesions, Removal or lightening of unwanted hair with orwithout adjuvant preparation
Comparison:	The RevLite Laser System with LCD Panel is comparable to itspredicate and parent devices in terms of its indications for use,technical specifications, operating performance features, andgeneral design features.
Nonclinical PerformanceData:	None
Clinical Performance Data:	none
Additional Information:	None requested at this time.

{1}------------------------------------------------

K063834

{2}------------------------------------------------

Image /page/2/Picture/12 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with its wings spread, and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES. USA" is arranged in a circular pattern around the eagle. The logo is black and white.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Hoya ConBio, Inc. % Ms. Donna K. Templeton Regulatory Consultant DKT Consulting 1105 Sunset Creek Lane Pleasanton, California 94566

JAN 2 5 2007

Re: K063834

Trade/Device Name: RevLite™ Q-Switched Nd: YAG Laser Systeml Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: Class II Product Code: GEX Dated: December 22, 2006 Received: December 27, 2006

Dear Ms. Templeton:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

{3}------------------------------------------------

Page 2 – Ms. Donna K. Templeton

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115 Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours

Mark N. Miller

Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

510(k) Number (if known): Ko6 3834

RevLite Q-Switched Nd: YAG Laser System Device Name:

Indications for Use:

Specific Indications

1064 nm wavelength:

Tattoo Removal: Dark Ink: (Black & Blue)

Nevus of Ota

Removal or lightening of unwanted hair with or without adjuvant preparation.

Skin resurfacing procedures for the treatment of acne scars and wrinkles

532 nm wavelength (nominal delivered energy of 585nm and 650 nm with the Optional Multilite Dye Laser Handpiece):

Tattoo Removal: Light Ink (Red, Sky Blue, Green)

Treatment of Vascular Lesions including, but not limited to:

. Prot wine birthmarks
Telangiectasias .
Spider angioma .
Cherry angioma .
Spider nevi .

Treatment of Pigmented Lesions including, but not limited to:

Café-au-lait bithmarks .
Solar lentiginos .
Senile lentiginos .
Becker's nevi .
Freckles .
Nevus spilus .

Skin resurfacing procedures for the treatment of acne scars and wrinkles.

Prescription Use	X	AND/OR	Over-The-Counter Use
(Part 21 CFR 801 Subpart D)			(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE

OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Division of General, Restorative,

and Neurological Devices

(Posted November 13, 2003)

Proprietary Information	510(k) Number	Page 178	L063 834	Page ___ of ___
-------------------------	---------------	----------	----------	-----------------

Regulation Number and Section

§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.

(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.